International Journal of Molecular Sciences (Nov 2022)

In Vitro and In Silico Analysis of New n-Butyl and Isobutyl Quinoxaline-7-carboxylate 1,4-di-<i>N</i>-oxide Derivatives against <i>Trypanosoma cruzi</i> as Trypanothione Reductase Inhibitors

  • Alonzo González-González,
  • Oscar Sánchez-Sánchez,
  • R. Luise Krauth-Siegel,
  • Maria Laura Bolognesi,
  • Rogelio Gớmez-Escobedo,
  • Benjamín Nogueda-Torres,
  • Lenci K. Vázquez-Jiménez,
  • Emma Saavedra,
  • Rusely Encalada,
  • José Carlos Espinoza-Hicks,
  • Alma D. Paz-González,
  • Gildardo Rivera

DOI
https://doi.org/10.3390/ijms232113315
Journal volume & issue
Vol. 23, no. 21
p. 13315

Abstract

Read online

American trypanosomiasis is a worldwide health problem that requires attention due to ineffective treatment options. We evaluated n-butyl and isobutyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives against trypomastigotes of the Trypanosoma cruzi strains NINOA and INC-5. An in silico analysis of the interactions of 1,4-di-N-oxide on the active site of trypanothione reductase (TR) and an enzyme inhibition study was carried out. The n-butyl series compound identified as T-150 had the best trypanocidal activity against T. cruzi trypomastigotes, with a 13% TR inhibition at 44 μM. The derivative T-147 behaved as a mixed inhibitor with Ki and Ki’ inhibition constants of 11.4 and 60.8 µM, respectively. This finding is comparable to the TR inhibitor mepacrine (Ki = 19 µM).

Keywords